Apricus Biosciences Inc (APRI)

1.28
0.01 0.39
NASDAQ : Health Care
Prev Close 1.29
Open 1.30
Day Low/High 1.24 / 1.34
52 Wk Low/High 0.32 / 1.99
Volume 136.06K
Avg Volume 90.00K
Exchange NASDAQ
Shares Outstanding 7.73M
Market Cap 9.82M
EPS -3.80
Div & Yield N.A. (N.A)

Latest News

Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback

Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback

Apricus Re-Affirms Plans to Re-Submit Vitaros U.S. NDA

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece

Recordati Targeting Launch in Greece in First Half of 2017

Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati

Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati

Continued Commercial Expansion in Europe Expected to Increase Royalty Revenue for Apricus

Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals

Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals

Ferring Demonstrates Continued Progress Towards Building the Vitaros Brand in Europe

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina

First Vitaros Approval in Latin America, Registrations Also Filed in Mexico and Colombia

Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati

Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati

To be Commercialized in Portugal and Ireland as Vitaros® and in Poland as Vytaros®

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital

$7.0 Million Equity Facility with Existing Long-Term Shareholder

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016